Procaps Group, S.A Return on Investment 2020-2023 | PROCF
Current and historical return on investment (ROI) values for Procaps Group, S.A (PROCF) over the last 10 years.
Procaps Group, S.A ROI - Return on Investment Historical Data |
Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
2023-09-30 |
$0.03B |
$0.26B |
20.53% |
2023-06-30 |
$0.04B |
$0.20B |
27.21% |
2023-03-31 |
$0.04B |
$0.16B |
32.39% |
2022-12-31 |
$0.04B |
$0.03B |
31.97% |
2022-09-30 |
$0.07B |
$0.16B |
48.59% |
2022-06-30 |
$0.07B |
$0.15B |
50.17% |
2022-03-31 |
$0.07B |
$0.15B |
65.75% |
2021-12-31 |
$0.07B |
$0.14B |
96.89% |
2021-09-30 |
$0.29B |
$0.15B |
465.04% |
2021-06-30 |
$0.28B |
|
1162.89% |
2021-03-31 |
$0.27B |
|
1096.91% |
2020-12-31 |
$0.27B |
$0.10B |
1096.91% |
2020-09-30 |
$0.01B |
|
inf% |
2019-12-31 |
$0.00B |
|
nan% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.125B |
$0.410B |
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.
|